MustGrow Biologics: Innovative Natural Fertilizer and Pesticide Solutions for Multiple Crops

MustGrow Biologics has launched its campaign on the Investing News Network’s Cannabis channel.

MustGrow Biologics is an agricultural biotech company that is developing and commercializing its unique natural biofumigant, which acts as a fertilizer, nematocide and fungicide. MustGrow’s product is based on brassica plants, a genus of the mustard family.

The company’s target markets are the fruit, vegetable and cannabis industries. Its product has been tested on fruits and vegetables in 110 different trials, and has proven that it can protect plants from fungal diseases and pests. The company is currently working on determining the product’s efficacy for cannabis crops. Having first created a granular product, MustGrow is now developing a liquid version that can be easily delivered to plants via existing drip systems.

MustGrow Biologics’ company highlights include the following:

  • Proprietary natural, organic biofumigation solution for addressing pests and diseases in cannabis, and fruit and vegetable crops
  • 110 trials conducted in fruit and vegetables, determining protection from a number of soil borne pets and fungal diseases including nematodes, pythium and fusarium.  
  • ETA approval across all key US states as a fertilizer and pesticide (currently limited to fertilizer in California)
  • Health Canada designation as a fruit and vegetable fertilizer and pesticide
  • Developing liquid format of tested product in response to market demand
  • Growing global biopesticide crop protection market potentially worth $7 billion by 2019
  • Planned CSE listing 
  • Experienced management team supported by director Tom Flow, who brings vast cannabis sector experience

Click here to see the educational profile for MustGrow Biologics and to request an investor presentation.

TCMD, PT & ACB Class Actions Deadlines: Bronstein, Gewirtz & Grossman LLC Reminds Investors of Class Actions and Lead Plaintiff Deadlines

Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss, you can request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. A lead plaintiff acts on behalf of all other class members in directing the litigation. The lead plaintiff can select a law firm of its choice. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff

Tactile Systems Technology (NASDAQ:TCMD)
Class Period: May 7, 2018 – June 8, 2020
Deadline: November 30, 2020
For more info: www.bgandg.com/tcmd

Keep reading... Show less

PharmaTher Provides Update on its Psychedelic Pharmaceuticals Programs

PharmaTher Inc., a wholly-owned subsidiary of Newscope Capital Corporation (“PharmaTher”) (CSE: PHRM) and a specialty life sciences company focused on the research and development of psychedelic pharmaceuticals, is pleased to provide a corporate update on its psychedelic pharmaceuticals program. Since its inception, the Company has built a unique product pipeline for novel uses of ketamine, psilocybin and undisclosed psychedelics. PharmaTher is positioning itself to partner its psilocybin program and panaceAI™, and focus on advancing its novel ketamine product pipeline in Parkinson’s disease, depression and pain via the U.S. Food and Drug Administration (“FDA”) regulatory pathway.

“We have made tremendous progress over the last several months that saw our product pipeline evolve to focus on the massive opportunity and potential of ketamine, an FDA approved drug with a known safety profile, to treat significant unmet medical needs for Parkinson’s disease, depression and pain,” said Fabio Chianelli, CEO of PharmaTher. “With our focus on ketamine through repurposing, combining it with an FDA approved drug and delivering it with our novel microneedle delivery system, we are now positioned to expedite our clinical development objectives by taking advantage of the FDA’s 505(b)(2) regulatory pathway and commercializing disruptive ketamine treatments for mental health and pain disorders.”

Keep reading... Show less

CEO’s of Tilray, Icanic Brands, Canopy Growth, and Aurora Cannabis Discuss Next Phase of Global Growth Opportunities and Brands Innovation

Wall Street Reporter, the trusted name in financial news since 1843, has published reports on the latest comments and insights from leaders at: Tilray, Inc. (NASDAQ: TLRY), Icanic Brands (OTC: ICNAF) (CSE: ICAN), Aurora Cannabis (NYSE: ACB)(TSX: ACB), and Canopy Growth Corporation (NASDAQ: CGC) (TSX: WEED).

Cannabis leaders are focusing on innovation in premium branding, global expansion, and tight operational execution in the drive towards profitability. Wall Street Reporter highlights the latest comments from industry thought leaders:

Keep reading... Show less

Chemesis International Inc. Announces Sale of Puerto Rico Operations

Chemesis International Inc. (the “Company”) (CSE:CSI)(OTCQB:CADMF)(FRA:CWAA

The Company announces that its (former) subsidiary, Natural Ventures PR, LLC (“NVPR”), has sold all of its cannabis assets, and assigned all related liabilities, licenses and permits, to Puerto Rico Industrial Commercial Holdings Biotech Corp. (“PRICH”) in exchange for immediate net cash proceeds to the Company, in respect of its 80% interest in NVRP, of US$450,000. The Company notes that, in connection with, and as a condition to, this transaction, it will cease to be a shareholder of NVPR.

Keep reading... Show less

PLAN Sells Private Company Shares to Finalize Focus on BC Assets

Progressive Planet Solutions Inc. (TSXV: PLAN) (“PLAN” or “Progressive Planet”), an emerging leader in reducing the carbon footprint of cement products using natural pozzolans, is pleased to announce it has sold and optioned a combined total of 10 million of its 10.5 million shares of Snow Lake Resources.

The sale and option agreements were made with two arms-length purchasers. The first sale was for 1,700,000 shares at $0.04 per share for a total of $68,000 and includes an option granted by PLAN entitling the same party to purchase an additional 4,966,666 shares at $0.04 per share until May 11, 2021 . The second sale was for 1,250,000 shares at $0.04 per share for a total of $50,000 and includes an option granted by PLAN to such party to purchase an additional 2,083,334 shares until August 14, 2021 . As at the date of this news release, PLAN has received $116,000 and will receive another $284,000 if the remaining shares are purchased under the option agreements.

Keep reading... Show less